CRDF

Cardiff Oncology, Inc. (CRDF) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Cardiff Oncology, Inc., a clinical-stage biotechnology company focused on PLK1 inhibition for cancer treatment. The report covers the quarterly and six-month periods ended June 30, 2026. The Company's lead asset, onvansertib, is currently in a Phase 2 trial for RAS-mutated metastatic colorectal cancer (mCRC) and is being evaluated in investigator-initiated trials for other indications.

Key Financial Metrics

Note: Revenue consists of royalty revenues from legacy intellectual property licenses unrelated to onvansertib.

Material Changes vs. Prior Period

• Revenue Decline: Royalty revenues decreased to $104,000 for the quarter (from $121,000 in Q2 2025) and $145,000 for the six months (from $230,000 in the prior year period).
• Reduced Operating Loss: Net loss for the quarter improved to $(9.2) million from $(13.9) million in Q2 2025. For the six months, the loss was $(21.6) million compared to $(27.4) million in the prior year.
• R&D Expense Reduction: Research and development expenses decreased significantly by $5.7 million for the quarter and $9.4 million for the six months. Management attributes this to the completion of certain clinical trials and a reduction in pre-clinical activities as the company focuses on the upcoming Phase 3 mCRC trial.
• SG&A Expense Increase: Selling, general, and administrative expenses increased by $0.5 million for the quarter and $2.6 million for the six months. This increase is primarily driven by attorney costs related to the intellectual property dispute with NMS and severance costs for former executives.
• Liquidity Position: Total cash, cash equivalents, and short-term investments decreased from $58.3 million at December 31, 2025, to $34.5 million at June 30, 2026, due to operating cash outflows.

Outlook, Risks, and Contingencies

• Going Concern Uncertainty: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern. Current capital resources ($34.5 million) are not sufficient to meet funding requirements for at least the next 12 months. The Company expects to fund operations into the third quarter of 2027 based on current projections but requires additional financing.
• Subsequent Financing: On July 14, 2026, the Company completed a registered direct offering, selling 8,571,429 shares and accompanying warrants for gross proceeds of approximately $10.1 million.
• Material Litigation: The Company is engaged in significant litigation with its licensor, Nerviano Medical Sciences S.r.l. (NMS). NMS alleged a material breach regarding inventorship on patents and purportedly terminated the license agreement in May 2026. Cardiff Oncology has filed a lawsuit seeking injunctive relief and a declaratory judgment that no breach occurred. A loss of rights under this agreement would have a material adverse effect on the business.
• Clinical Progress: Data from the Phase 2 mCRC trial (CRDF-004) presented in June 2026 showed the 30 mg onvansertib arm achieved a 72.2% objective response rate compared to 42.1% for standard of care. The Company has completed its End-of-Phase 2 meeting with the FDA and is designing the registrational Phase 3 trial.

Key Facts for Investor Verification

• Runway and Funding Needs: Verify the sufficiency of the $10.1 million raised in July 2026 combined with existing cash to fund the Phase 3 trial and operations through the next 12 months, given the "substantial doubt" disclosure.
• Litigation Outcome: Monitor the status of the lawsuit against NMS regarding the onvansertib license. The potential loss of this license poses an existential risk to the Company's primary asset.
• Phase 3 Trial Initiation: Confirm the timeline and enrollment progress for the registrational Phase 3 trial (CRDF-005) in RAS-mutated mCRC, which is critical for future commercialization.
• Expense Management: Track the trajectory of SG&A expenses, specifically legal fees related to the NMS dispute, to ensure they do not accelerate cash burn beyond projections.